News Releases

View all Historical Press Releases

Investor Alerts

Aug 22, 2018

Soligenix Receives US Patent for Improved Production of Synthetic Hypericin

Active Ingredient in SGX301 for the Treatment of Cutaneous T-Cell Lymphoma

PRINCETON, NJ – August 22, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Aug 8, 2018

Soligenix Announces Recent Accomplishments And Second Quarter 2018 Financial Results

PRINCETON, NJ – August 8, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Jul 26, 2018

Soligenix Announces a RiVax® Program Presentation at the 31st Annual Congress on Vaccines, Clinical Trials & B2B in Vancouver, Canada

Princeton, NJ – July 26, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Jul 24, 2018

Soligenix Announces Appointment of Mark Pearson to its Board of Directors

Princeton, NJ – July 24, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Jul 19, 2018

Soligenix – Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials

Company provides mid-year update and guidance

Princeton, NJ – July 19, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...

Show per page